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Objectives: To establish the key drivers of purchasing, pricing, access, and 
profitability for biologics in markets where biosimilars, bio-originals, and new 
innovative biologics compete. To provide insight into how sustainability, profit, 
pricing and access are driven by differentiation. MethOds: A meta-analysis 
was conducted across all studies (n= 14) undertaken by GfK since January 2014 
involving the pricing and market access of biologics in Europe in inflammatory 
disease and oncology. The studies involved primary research, system dynamics 
modelling, and war gaming (competitive simulation). Primary research com-
prised interviews (n= 250) across 7 European markets: France, Germany, Hungary, 
Italy, Poland, Spain and the UK, collecting insight at pan-European, National and 
Regional levels, Physicians, Payers, Patients, and Industry. System dynamics mod-
elling, based on delphi panels of expert opinion, focused on 2 oncology products 
(trastuzumab, bevacizumab) and 3 anti-TNFs (infliximab, etanercept, adalimumab). 
War gaming was used to explore the forces of supplier and buyer power, impact 
of new entrants, impact of substitutes, and competitive rivalry. The impact of 
price referencing was included in the analysis, as was consideration of parallel 
trade. Results: The analysis showed that the key drivers of purchasing, access, 
and profitability in markets where biosimilars compete are product differentiation, 
relative effective net pricing, and multi-criteria decision-making. Both sustain-
ability and profitability are driven by differentiation. War gaming indicates that 
a market that recognizes these drivers and dynamics will deliver benefits to all 
stakeholders, including the opportunity for cost savings that can be used to fund 
access to the next generation of innovative new high cost / high value thera-
pies. cOnclusiOns: Acceptance of multi-criteria decision making that includes 
non-price criteria, a willingness to pay for differentiation, and the evolution of 
policies relating to interchangeability, substitution and switching will increase 
the stability, sustainability and profitability of markets that include biosimilars.
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Objectives: Medication persistence and adherence are important to treat-
ment success, particularly where target level achievement is critical, as in gout. 
Identifying barriers provides opportunity to improve patient outcomes. The objec-
tive is to evaluate persistence and adherence of allopurinol (ALLO) new users as 
well as relation to clinical determinants. MethOds: We assessed profile of ALLO 
use among a cohort of new ALLO users after starting an antihypertensive agents, 
using RAMQ and MED-ECHO Québec administrative databases. New ALLO users 
aged 45-85 yrs with ≥ 1 claim from Jan 1997-Jun 2007 were included. New users 
were defined as having no ALLO prescribed in the 1 yr prior to cohort entry. Cohort 
entry was defined by date of 1st ALLO claim. Adherence level was assessed by med-
ication possession ratio (MPR) and cumulative persistence rates by Kaplan-Meier 
analysis. Adjusted Cox regression models estimated rate ratio of ceasing ALLO. 
Logistic regression models established relation between non-adherence level and 
their determinants. Results: Of 2752 patients, mean age was 70 (63-76) yrs, 82% 
men. Close to 50% had ≥ 1 cardiovascular disease, dyslipidemia (33%), diabetes 
(21%), CKD (15%), and rheumatic disease (6.3%). Patients included users of low-dose 
aspirin (33%) and NSAIDs (42%). During the 1st yr, MPR was 71% and high adher-
ence (MPR ≥ 80%) was 57%. Persistence decreased to 47% after 1-yr follow-up. Non-
persistence was more likely in patients with rheumatic disease (by 25%) and in 
NSAID users (by 18%). For previous ALLO users, persistence was increased by 29%. 
Persistence was higher for intra-articular corticosteroid users (by 18%), patients 
who had had a prior use of ALLO (29%), users ≥ 7 medications (by 39%). Non-
adherence determinants were similar to those of non-persistence. cOnclusiOns: 
Barriers to persistence/adherence occur early during ALLO therapy. Adherence is 
key to determine success of many treatment approaches; greater attention may 
result in improved outcomes.
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Objectives: Biologics are drugs with a large economic burden for health care 
providers and should only be given to patients with a sever autoimmune disease 
like rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis(PS). 
The aim of this study was to evaluate the prescription reality of biologics within 
these diagnoses. MethOds: To examine the prescription reality of biologics, 
prescriptions of a large German claims data base were evaluated. Demographic, 
prescription and diagnosis data was taken from 2007 to 2013 to identify the pre-
scription routine on a yearly basis. This study included 42,441 to 92,059 patients 
per year suffering from RA, PS or AS and their observed prescriptions of biologics. 
Patients were only included if they were fully observable in the specific year of 
analysis. Results: The underlying base population of the whole claims data base 
(n = 3,6m) is fairly comparable to the overall German population regarding age, 
gender, morbidity and mortality. In 2013 84,645 AS patients, 37,839 PS and 56,570 
RA patients could be observed, where 58,45% are female (mean age = 57,55 years). 
Overall, the prescription ratio of biologics increased from 1,61% in 2007 to 3,43% in 
2013. Concerning gender, no difference in the probability of biologics prescriptions 
could be observed (57,43 % of biologics patients were female). However, a sharp 
drop in the prescription of biologics for elderly patients is present (5,8% 30-39y; 
5,5%40-59y vs 3,1% 60-69; 1,74%70-79; < 0,65% 80+). In contrast to this result, 
patients with a disease combination receive biologics more frequently (MS+AS+PS: 
29,89% vs. AS: 5,96%, PS: 2,04%, RA:9,79%). cOnclusiOns: Although the frac-
tion of patients with biologics increased in the last years, old people seem to be 
obtained from outpatient drug prescriptions, hospital discharges and ambulatory care 
records collected from January 1, 2005 to December 31, 2008. The study was designed 
as a retrospective study cohort. Patients 60 years of age or older were included if at 
least one prescription for any antiosteoporotic drugs. had been filled in between 
January 1, 2006 and December 31, 2006. For each patient, the following characteristics 
were considered:gender, age, dosing regimen, previous treatments, previous frac-
tures, co-prescription of calcium/Vitamin D, spot therapy, switcher, comorbidity. The 
primary outcome of this study was persistence at one year; the secondary outcome 
was hospitalized osteoporotic fractures based on ICD-9 codes related osteoporotic 
fracture. Results: The final cohort consisted of a total of 7,862 patients, aged > 60 
years. Kaplan – Meier analysis showed that 3,733 patients (47.5%) were persistent 
with antiosteoporotic drugs after 1 year. In the logistic regression analysis adjusted 
for potential confounders odds of fracture were significantly lower for persistent 
patients (OR:0.79). Older patients were more likely to incur a fracture than younger 
[70-79 years(OR:1.52), ≥ 80 years (OR:2.49)]. The odds of fracture were significantly 
higher for patients with previous fractures in comparison with those without previous 
fractures (OR: 1.70). cOnclusiOns: The current analysis demonstrates a significant 
association between risk of fracture and persistence. Persistence to therapy with 
antiosteoporotic drugs is important for the effectiveness of osteoporosis treatment. 
Improving osteoporosis treatment compliance and persistence is an important chal-
lenge for clinicians and the society as a whole.
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Objectives: Argentinean health system is divided in 3 subsectors: Social Security 
(48%), Public (42%) & Private (10%). It is known that the public one is the one 
with the biggest gaps in terms of capabilities, infrastructure and budget capacity 
and the most fragmented (24 differents states without standarized procedures). 
However, no local data is available regarding the accessability to biologics for the 
treatment of Rheumatoid Arthritis. The aim of the study is to describe the actual 
picture of biologics availability in the public sector, rheumatologist perception 
about main barriers and finally, to describe potential solutions. MethOds: A sur-
vey to 200 rheumatologist (Rheumatologist population in the whole country is 
witihin 400 - 600) was sent using gForms with the aim to describe the avalability of 
synthetics DMARD, biologics DMARD and targeted synthetic DMARD (Tofacitinib); 
main barriers according rheumatologist perception and budget management was 
also assessed. Results: 80% of the rheumatologist expressed that biologics are 
not avaialble in the public sector as a regular treatment, just as an “exception”. 
Among these spontaneously availability Adalimumab, Rituximab, Etanercept and 
Tocilizumab were the most named. Surprisingly, synthetic (classic) DMARD like 
metotrexate is available with severe impairements in the delivery. Main barrier 
to obtain biologics according rheumatologist perception is the restrictive budget 
allocation in the Institution, followed by biologic prices. cOnclusiOns: The pre-
sent study is the first one regarding biologic availability in the public sector in 
argentina. Big gap is seen when talking about RA treatments, moreover when a 
biologic is prescribed. Potential solutions might be: differential prices for differents 
sector, centralized drug purchasing, well design copayments, and others to be 
descripted in the poster. Full references, questionnaire with other responses and 
potential solutions are to be described in the poster.
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Objectives: Biologics are used for treatment of different diseases from cancer to 
autoimmune diseases. According to IMS biologics share in total pharma market 
in 2002 was 11% and will reach 19-20% of market share in 2017. This class of drug 
bears high costs and this is the main reason of low access to these therapies in 
developing and low income countries. Due to the costs access to this therapeutics 
depends on public funding. We examined access and trends of consumption of 
novel biologics in Bosnia and Herzegovina. MethOds: Data on consumption of 
biologics was generated from official report on annual pharmaceutical expenditure 
published by State agency for medicines and medical devices. We covered 6-years 
period (2009-2014). Access to biologics depends on public funding and has direct 
impact on expenditure and these data have been taken from official reimbursement 
lists of Health Insurance Funds financing expensive medicines. Data on expenditure 
are represented in value (EUR) and analysis did not consider volume sales. Results: 
Market share of biologics in total B&H pharma-market in 2009 was 4% and increased 
to 8% in 2014 which is highly below global trend. Monoclonal antibodies for can-
cer are present at reimbursement lists from 2009 showing constant sales growth. 
Trastuzumab is most used biologic (1,9m€ in 2009 and 6,9m€ in 2014), followed by 
rituximab, sunitinib, sorafenib and bevacizumab. Impact of reimbursementis best 
shown in case of sunitinib and sorafenib with high sales increase reflecting medi-
cal need for these therapies. Imatinib sales significantly dropped after biosimilar 
introduction into the market in 2013. Lapatinib and nilotinib had been introdudec 
into the market in 2010 and palivizumab and adalimumab in 2011 showing constant 
sales growth cOnclusiOns: Access to novel biologic depends on public funding 
and there is significant need to these therapies . Biosimilar introduction into market 
can significantly improve access to these therapies and decrease costs
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